Thursday Sep 08, 2022

To boost or not to boost – Part 1

Just this week, the CDC and FDA gave the green light to distribute updated bivalent COVID boosters that target the original virus and also Omicron subvariants BA.4 and BA.5. On this episode, we begin a two-part discussion over the science and rationale behind the new vaccines.

Guest speaker:
Azra Behlim, PharmD, MBA
Associate Vice President, Pharmacy Sourcing and Program Services
Vizient

Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Senior Principal, Clinical Operations and Quality
Vizient

Show Notes:

[00:54] How the new vaccine type is different

[01:45] Shorter vaccine approval and turnaround

[02:45] COVID virus mutations and immunity

[04:50] Rationale for alternating vaccines

[05:53] Upcoming human studies

[07:47] Vaccine eligibility

Links | Resources:

To contact Modern Practice: modernpracticepodcast@vizientinc.com

FDA announcement on new vaccine boosters (8-31-22): Click here